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Abstract: The increasing number of patients receiving home respiratory therapy (HRT) is imposing
a major impact on routine clinical care and healthcare system sustainability. The current challenge is
to continue to guarantee access to HRT while maintaining the quality of care. The patient experience
is a cornerstone of high-quality healthcare and an emergent area of clinical research. This review
approaches the assessment of the patient experience in the context of HRT while highlighting the
European contribution to this body of knowledge. This review demonstrates that research in this area
is still limited, with no example of a prescription model that incorporates the patient experience as
an outcome and no specific patient-reported experience measures (PREMs) available. This work also
shows that Europe is leading the research on HRT provision. The development of a specific PREM
and the integration of PREMs into the assessment of prescription models should be clinical research
priorities in the next several years.
Keywords: Long-term oxygen therapy; home mechanical ventilation; patient-reported experience
measures; quality of care; healthcare; sustainability
1. Introduction
Long-term oxygen therapy (LTOT) and/or home mechanical ventilation (HMV) are well-established
therapies for patients with chronic respiratory failure, such as those with chronic obstructive pulmonary
disease (COPD), neuromuscular diseases, and obstructive sleep apnea (OSA), among others. These
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therapies represent key services in the home respiratory therapy (HRT) provided to these patients.
Increasing numbers of patients receiving HRT are reported not only in Europe but also worldwide [1–5].
Thus, HRT is imposing a major impact on clinical care and healthcare systems. Over the next several
years, the main challenge will be to ensure a sustainable healthcare system to continue to guarantee
access to HRT while maintaining the quality of care.
According to the World Health Organization, quality of care is defined as “the extent to which health
care services provided to individuals and patient populations improve desired health outcomes. In order to
achieve this, health care must be safe, effective, timely, efficient, equitable and people-centered” [6].
A necessary step in the process of maintaining and improving quality is to monitor and evaluate the quality
of healthcare in routine clinical practice. Based on the reactive, disease-focused, and biomedical model,
the indicators of quality have been mainly restricted to traditional clinical metrics. A number of studies
conducted over the last few decades have addressed the beneficial effects of HRT on morbidity, mortality,
and adverse outcomes, as well as the variations in HRT provision among countries [5,7,8]. However, these
metrics alone do not provide a complete picture of HRT quality.
The patient’s experience of treatment is a cornerstone of high-quality healthcare [9]. Only by
analyzing the relational and functional aspects of the patient experience is it possible to assess the
extent to which patients are receiving care that is in line with their preferences, needs, and values.
The integration of the patient experience with healthcare delivery and quality evaluation are key steps
in moving toward patient-centered and personalized care [10]. As Doyle et al. suggested, the patient’s
experience is the third pillar of quality, along with clinical safety and effectiveness [11]. However, it is
only in recent years that patients’ perceptions of healthcare provision have started to receive attention.
This review approaches the assessment of the patient experience in the clinical context of HRT
while highlighting the European contribution to this emerging body of knowledge.
2. Patient Experience in the Context of HRT
The patient experience in the context of HRT is reviewed with a focus on two main areas: (1)
HRT prescription models and the inclusion of the patient experience as an outcome of these models
and (2) methods used to assess the patient experience. To address these two aims, a narrative
review was conducted. The search, although not systematic in nature, included searches in electronic
databases (PubMed, Medline, ISI Web of Knowledge and Google Scholar), as well as hand searches
(expert consultation and a review of the reference lists in the included papers). The databases were
searched between July and December 2018 using topic-related terms, such as oxygen therapy, home
mechanical ventilation, noninvasive mechanical ventilation, home respiratory therapy, home treatment,
chronic respiratory insufficiency, chronic respiratory failure, epidemiology, prescription, quality control,
outcomes, patient experience, patient perspective, carers, caregivers, patient-reported experience
measure, questionnaires, interviews, and focus groups. There was no time restriction in the literature
search, although it was limited to English, Portuguese, or Spanish.
2.1. Prescription Models of HRT
There are a number of studies that have assessed the prescription of HRT. Table 1 summarizes 15
relevant studies on this topic. The majority of the studies (n = 9) were conducted from 2009 onward
and primarily assessed the prescription of HMV (n = 10) [4,5,12–19], followed by LTOT (n = 6) [19–24].
The estimated prevalence of HMV (from 2.5 to 23/100,000 population) and of LTOT (from 31.6 to
102/100,000 population) were variable among distinct regions or countries. The estimated prevalence
of HMV in Europe was 6.6 per 100,000 people, and Portugal was one of the countries with the highest
prevalence [5].
Three studies reported the assessment of HRT prescription at a regional level (Catalan, Spain;
Hong Kong, China; Tasmania, Australia), eight at a national level (Sweden, Canada, Poland, Denmark,
England, Australia, France, Spain), and four at an international level (two countries, seven countries,
13 European countries, 16 European countries).
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Table 1. Studies assessing the prescription of home respiratory therapies.
Author,
Year
Region or Country,
Years Analyzed Aim Method Data Collection Results
Ekström et al.,
2017 [20] Sweden, 1987–2015
Long-term oxygen
therapy (LTOT): incidence,
prevalence, and the
quality of prescription
and management
Data from the Swedevox registry
between 1 January 1987 and 31
December 2015
Data:
Birth date,
Sex,
Primary/secondary causes of LTOT,
Follow-up,
Stop date and stop cause,
PaO2 air and PaCO2 air,
PaO2 oxygen and PaCO2 oxygen,
FEV1 and VC,
World Health Organization performance status,
Height and weight,
Never/Past/Current smoker,
Maintenance treatment with oral corticosteroids,
Oxygen dose,
Oxygen duration.
23,909 patients on LTOT.
48 respiratory or medicine units.
Incidence of LTOT increased from 3.9 to
14.7/100,000 inhabitants over the study time
period.
In 2015, 2596 patients had ongoing therapeutic
LTOT in the registry, a prevalence of 31.6/100,000.
Adherence to prescription recommendations and
fulfilment of quality criteria were stable or
improved over time.
Of patients starting LTOT in 2015, 88% had severe
hypoxemia and 97% had any degree of hypoxemia;
98% were prescribed oxygen for ≥15 hours/day;
76% had both stationary and mobile oxygen
equipment; 75% had a mean PaO2 > 8.0 kPa
breathing oxygen; and 98% were non-smokers.
Rose et al.,
2015 [12] Canada, 2012–2013
Home mechanical
ventilation (HMV):
national data profiling
Survey administered via a web
link from August 2012 to April
2013 to service providers
delivering care/services to
ventilator-assisted individuals
requiring daily noninvasive
ventilation (NIV) or invasive
mechanical ventilation via
tracheostomy at home.
Survey content:
provider characteristics, including services and
education provided;
user characteristics (age, ventilation type, primary
disorder, duration of ventilation);
criteria for initiation and monitoring ventilation
effectiveness; equipment (ventilators and
interfaces used, ventilator servicing arrangements
and backup);
training and education (audience, structure, topics,
ongoing competency assessment);
liaisons and transitions (referral, barriers to
transition);
follow-up (structure, frequency, location).
Response rate 152/171 (89%).
4334 ventilator-assisted individuals: an estimated
prevalence of 12.9/100,000 population.
73% receiving NIV and 18% receiving intermittent
mandatory ventilation (9% not reported).
Services were delivered by 39 institutional
providers and 113 community providers.
Various models of ventilator servicing were
reported.
64% of providers stated that caregiver competency
was a prerequisite for home discharge, but
repeated competency assessment and retraining
were offered by 45%.
Barriers to home transition: insufficient funding
for paid caregivers, equipment, and supplies;
a shortage of paid caregivers; negotiating public
funding arrangements.
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Author,
Year
Region or Country,
Years Analyzed Aim Method Data Collection Results
Escarrabill et al.,
2015 [13]
Catalan Health
Service (Spain),
2008–2011
HMV: prevalence and
variability in prescriptions
Catalan Health Service (CatSalut)
billing database, between 2008
and 2011.
Not reported (NR)
240,760 patients received some type of HRT
funded by the public system.
75.8% used continuous positive airway pressure
equipment, 17.3% used various forms of oxygen
supply, 4.2% used nebulized therapy, 2.5% used
HMV, and 0.2% used miscellaneous treatments.
6,867 patients received HMV, 23 users per 100,000
population.
Rates of HMV increased by 39% over the study
period
Nasiłowski et al.,
2015 [14] Poland, 2000–2010
HMV: trends over the last
decade
Questionnaire designed
specifically for the study was sent
to the heads of nine HMV centers
Survey Content:
Center details: location, area of activity
(uniregional/multiregional), and year of initiating
HMV.
Number of subjects treated with HMV in each
consecutive year.
Overall number of treated subjects, divided into
five disease categories:
(1) neuromuscular diseases,
(2) lung diseases (chronic obstructive pulmonary
disease (COPD), bronchiectasis, cystic fibrosis,
interstitial diseases),
(3) chest-wall diseases (scoliosis, thoracoplasty,
ankylosing spondylitis, post-tuberculosis
sequelae),
(4) hypoventilation syndromes (due to obesity,
central congenital hypoventilation syndrome,
central sleep apnea),
(5) other diseases.
Technique of ventilation (invasive and
noninvasive).
Number of new cases;
Overall number of subjects treated with NIV or
tracheostomy.
Age of the treated subjects,
Site where ventilation was initiated: intensive care
unit, respiratory department, neurology
department, general medicine department, home,
or other.
Nine HMV centers, 1495 subjects
Center experience 9 ± 3 years (6–13 years)
One center was dedicated specifically to children,
Two solely treated adults, and other centers
treated subjects irrespective of age.
In 2010, prevalence of HMV reached almost 2.5
subjects/100,000.
The majority of subjects on HMV suffered from
neuromuscular diseases (100% in 2000–2002 to
51% in 2010).
Subjects with a diagnosis of respiratory failure
due to pulmonary conditions appeared in 2004,
and the number of subjects rapidly increased
beginning in 2007. In 2010, they accounted for
almost 25% of all HMV cases.
Hypoventilation syndromes were the third main
diagnostic group (4% until 2008, reaching 11% in
2010).
Proportion of chest-wall diseases remained ~3%.
In 2000 and 2001, ventilation via tracheostomy
was exclusively used.
The first subjects on NIV were treated in 2002. The
number of subjects on NIV was 1/3 in 2004 and
then leveled off for the following five years,
followed by a rapid increase until 2010, when the
proportions of subjects treated with NIV and
tracheostomy equalized. Since 2008, the number
of new cases treated noninvasively surpassed the
number of new cases treated with invasive
ventilation, and in 2010, the total number of
subjects in both groups was virtually the same.
J. Clin. Med. 2019, 8, 555 5 of 24
Table 1. Cont.
Author,
Year
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Years Analyzed Aim Method Data Collection Results
Garner et al., 2013
[15]
Australia and New
Zealand, 2002–2004 HMV
HMV centers that had prescribed
HMV for more than three months
to more than five adult patients.
A designed survey.
Survey Content:
(1) Institutional details: location, type (e.g.,
tertiary), funding (e.g., government), patient
catchment, years of service;
(2) Criteria for HMV prescription by disease group
(e.g., COPD);
(3) HMV service details: number of patients
receiving HMV, staffing levels, methods of
implementation by location/tests utilized/staff
involved, methods of follow-up by location/tests
utilized/staff involved (0–3 grading from never to
always), annual clinic attendances, presence of an
outreach service;
(4) Individual patient data (if available): age,
gender, primary indication for HMV, duration of
therapy, adherence to therapy, interface, machine
settings (mode, inspiratory positive airway
pressure, expiratory positive airway pressure,
back-up rate);
(5) Local database: current database for that center,
data collected, what data should be collected,
support for creation of a national database, center
willing to participate;
(6) Problems encountered with setting up an HMV
service.
28 centers (82%) responded, providing data on
2725 patients.
Prevalence of HMV was 9.9 patients/100,000 in
Australia and 12.0 patients/100,000 in New
Zealand.
Variation existed among Australian states (range
4–13 patients/100,000) correlating with population
density (r = 0.82, p < 0.05).
The commonest indications for treatment were
obesity hypoventilation syndrome (31%) and
neuromuscular disease (30%).
COPD was an uncommon indication (8%).
No consensus on indications for commencing
treatment was found.
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Year
Region or Country,
Years Analyzed Aim Method Data Collection Results
Ringbaek et al.,
2013 [21] Denmark, 2001–2010
(LTOT: incidence,
prevalence, treatment
modalities,
and survival in COPD.
Danish Oxygen Register in the
period from 01 January 2001 to 31
December 2010: information on
patients on home oxygen therapy,
their prescriptions, and
termination of therapy.
National Health Services Central
Register: information on
diagnosis for LTOT and on vital
status up to 31 December 2011.
NR
On 31 Dec 2001, a total of 2247 COPD patients
(42.0/100,000) were receiving LTOT.
The number of patients on LTOT had increased
constantly to reach a prevalence of 48.1/100,000 in
2010.
Incidence of oxygen therapy increased
insignificantly from 30.5 to 32.2/100,000.
The majority of COPD patients were women and
older than 70 years of age. The mean age of
patients who started LTOT during the study
period increased from 73.4 ± 9 years to 74.8 ± 9.7
years.
Most of the COPD patients were prescribed
oxygen therapy by a hospital doctor immediately
after an acute hospitalization, and the number of
prescriptions from general practitioners was
continuously declining toward zero during the
study period.
An increasing number of the COPD patients were
prescribed oxygen at least 15 h daily and had
delivered oxygen concentrator and mobile oxygen,
whereas, in general, the oxygen flow remained
low (≤1.5 L/minute).
Compared with men, women started LTOT more
often in connection with hospitalization and more
often stopped LTOT within the first 6 months.
Women were prescribed a lower oxygen flow than
men and the treatment was more often specified to
take place for 15–24 h per day.
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Author,
Year
Region or Country,
Years Analyzed Aim Method Data Collection Results
Mandal et al., 2013
[16] England, NA
HMV: prevalence of sleep
and ventilation diagnostic
and treatment services
A short survey delivered by
email to 101 NHS Hospitals
Survey content:
10-item survey, focused on diagnostic services and
HMV provision:
(a) availability of diagnostics,
(b) funding;
(c) patient groups.
76 (68%) responses received;
42 (55%) trusts reported the provision of an HMV
service.
Only 65% of units charged for the delivery of
an HMV service, with 12% of these services
commissioned by an external provider.
Median set-up frequency for the units charging
was 42 patients per annum (interquartile range
23–73), whereas those units that failed to charge
had a median of 11 (interquartile range 4–22).
Of all the HMV set-ups, 67% were for
obesity-related respiratory failure and COPD,
with the other restrictive lung conditions forming
the remainder
Serginson et al.,
2009 [22] Australia, 2004–2005
LTOT: prescription and
costs
Data from all LTOT services in
Australian Government’s
departments and health services
(state and federal)
Centralized departments
managing
state budgets for LTOT provided
costs (for the financial year
2004–2005) and patient numbers
(point prevalence in 2005).
If centralized data were not
available, regional departments
administering LTOT services
were contacted.
Data:
Costs were defined as “equipment only” (fees
paid to oxygen companies) or “equipment and
administrative” (wages and non-labor costs of
administering programs included).
20,127 patients (100/100,000) through 59 different
services at a cost of over $31 million.
Prescription rates for LTOT per 100,000 population
within each state ranged from 44 to 133, a
threefold difference.
Costs of LTOT per patient prescribed per year
funded by individual states and territories ranged
from $1014 to $2574.
The cost of oxygen concentrators averaged $85 per
month (range, $29–$109), portable oxygen ranged
from $16 to $35 per month without refills, and,
with a conserver included, $55 (two refills) to $166
unlimited refills) per month.
All services provided concentrators for home use.
Portable oxygen was funded in all states, except
one (where it was limited to children and patients
waiting for heart or lung transplants).
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Jones et al., 2007
[23]
Tasmania
(Australia),
2002–2004
LTOT
Records of all patients receiving
Tasmanian
Government-funded LTOT
between
December 2002 and April 2004
Data:
Recipient demographics,
Indications for LTOT,
Oxygen prescription,
Time to follow-up.
The service provider provided usage reports and
costs.
April 2004: 490 patients receiving LTOT
Rate of 102/100,000;
Median age at prescription of LTOT was 71.5
(range 0.7–97.2) years, and 54% of patients were
female.
Oxygen was prescribed for 267 patients (54%)
during hospitalization, although only 192 of these
patients (72%) met criteria for oxygen use at this
time.
LTOT was prescribed by respiratory physicians for
248 patients (51%) and by other hospital
physicians for most of the remaining patients
(39%).
Data on indications were available for 430 patients
(88%), and COPD accounted for 48% of
prescriptions, but this proportion varied regionally.
Median time to reassessment was 5.5 (range,
0.1–116) months, but varied between regions.
Usage data were available for 175 patients (41%)
using oxygen concentrators in April 2004. Of these
175 patients, 122 (70%) were prescribed oxygen for
COPD. In this group, the median use was 18.3
(range, 0.38–24) hours per day; however, 36 (30%)
had a median use < 15 hours/day.
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Lloyd-Owen et al.,
2005 [5]
16 European
countries (Austria,
Belgium, Denmark,
Finland, France,
Germany, Greece,
Ireland, Italy,
Netherlands,
Norway, Poland,
Portugal, Spain,
Sweden, UK),
2001–2002
HMV: patterns of use
across Europe
Questionnaire of center details,
HMV user characteristics and
equipment choices sent to
selected HMV centers
Survey Content:
Center (type of institution and year of starting
HMV),
Number of HMV users on 01 July 2001,
Users’ characteristics (sex, age, and time on HMV).
Users’ causes for respiratory failure:
(1) Lung: lung and airway diseases: COPD, cystic
fibrosis, bronchiectasis, pulmonary fibrosis, and
pediatric diseases, including bronchopulmonary
dysplasia;
(2) Thor: thoracic cage abnormalities: early-onset
kyphoscoliosis, tuberculosis sequelae such as
thoracoplasty, obesity hypoventilation syndrome,
and sequelae of lung resection;
(3) Neur: neuromuscular diseases: muscular
dystrophy, motor neuron disease (including
amyotrophic lateral sclerosis), post-polio
kyphoscoliosis, central hypoventilation, spinal
cord damage, and phrenic nerve paralysis.
Type of ventilator and interface used.
329 centers completed surveys, 21,526 HMV users;
Estimated prevalence of HMV was 6.6/100,000 in
the 16 European countries.
Differences between countries in the relative
proportions of (1) lung and neuromuscular
patients using HMV and (2) the use of
tracheostomies in lung and neuromuscular HMV
users.
Lung users were linked to an HMV duration of <1
year, thoracic cage users with 6–10 years of
ventilation and neuromuscular users with a
duration of ≥6 years.
Almost all of the HMV users had positive pressure
ventilators, with only 0.005% (79 users) having
other types. Volume preset positive pressure
ventilators were used the least for lung problems
and most frequently for neurological problems (%
volume: Lung 15%; Thor 28%; Neur 41%).
Overall, 13% of the survey population had
ventilation via a tracheostomy with the highest
percentage in neuromuscular patients (Neur 24%;
Thor 5%; Lung 8%).
Chu et al., 2004
[17]
Hong Kong (China),
2002 HMV
Survey to consultants of
respiratory
medicine in all adult medical
departments of Hong Kong
Hospital Authority hospitals to
report
their adult patients (>18 years)
who had ever
been managed by HMV
Survey content:
demographic data,
mode of ventilation (non-invasive or tracheostomy
ventilation),
underlying disease,
indications for HMV,
time of starting ventilation,
time and reason of stopping ventilation, if any, in
the follow-up period.
249 cases reported to the survey from 14 centers of
adult respiratory medicine;
156 males (62.7%) and 93 females (37.3%) with a
mean age of 62.7 ± 13.8 years;
80% of HMV cases were under the care of six
major centers.
197 cases were continuing with HMV,
corresponding to ~2.9 HMV users per 100,000
population.
The majority (n = 236, 94.8%) were treated by
noninvasive ventilation (NIV), with the remaining
13 patients (5.2%) receiving tracheostomy
ventilation.
All NIVs were provided by bilevel
pressure-support ventilators. All tracheostomized
cases were put on HMV after repeated failures to
wean.
The disease conditions for which HMV was
prescribed: COPD (121, 48.6%); Complicated
obstructive sleep apnea/obesity hypoventilation
syndrome (43, 17.2%); and Restrictive thoracic
disorders (85, 34.1%).
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Fauroux et al.,
2003 [18] France, 2000
Domiciliary non-invasive
mechanical ventilation
(NIMV) in children
Anonymous national
cross-sectional
Survey
A postal questionnaire sent by the
Paediatric Group of the National
Home Care Organization
(ANTADIR) in 1999 to all 64
senior pediatric respiratory,
neurology, and intensive care
physicians in France.
Patients aged < 18 years and
receiving home NIMV were
included in the study.
All physicians taking care of children with NIMV
were sent a second questionnaire in 2000.
The specific information requested on each patient
included:
Sex and date of birth;
Primary and secondary diagnosis;
Symptoms that justified NIMV;
Age at onset of NIMV;
Type of nasal mask, ventilatory mode, and
concurrent use of oxygen therapy;
Investigations performed before initiating of
NIMV and during follow-up.
102 patients from 15 centers: 4/15 centers cared for
84% of patients;
7% of patients were under 3 years; 35% were 4–11
years; and 58% were >12 years.
Underlying diagnoses included neuromuscular
disease (34%), obstructive sleep apnea and/or
craniofacial abnormalities (30%), cystic fibrosis
(17%), congenital hypoventilation (9%), scoliosis
(8%), and other disorders (2%).
NIMV was started because of nocturnal
hypoventilation (67%), acute exacerbation (28%),
and/or failure to thrive (21%).
Volume-targeted ventilation was preferred in
restrictive disorders (56%) and central
hypoventilation (56%), while pressure support
ventilation (PSV) was preferred in cystic fibrosis
(71%).
Patients with obstructive sleep apnea and/or
craniofacial abnormalities were ventilated with
continuous positive airway pressure (45%) or
bilevel PSV (52%).
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Wijkstra et al.,
2001 [24]
Seven countries
(Brazil, Canada,
France, Italy, Spain,
Netherlands, USA),
NR
LTOT: prescription
Questionnaire mailed to 100
randomly selected respirologists
from a list of respiratory
specialists belonging to a
professional organization in each
country
Characteristics of the respirologists:
Date of birth;
How many years they had been practicing
respiratory medicine;
Number of patients for whom they prescribed
oxygen for the first time or for renewal purposes
over the previous month.
Prescription of oxygen at rest;
Whether they prescribed a standard oxygen flow
rate for all their patients or whether they
individualized flow rates with or without specific
testing of each patient;
How the recommended oxygen flow at rest was
chosen (either tested at rest or tested during
exercise);
The position (sitting, semirecumbent, supine) in
which the patients were tested,
the target level of arterial oxygen saturation (SaO2)
used to establish an oxygen prescription and the
percentage of time during the measure in which
this target had to be achieved.
Prescription of oxygen during sleep and exercise;
How they prescribed oxygen during sleep and
exercise;
The type of exercise test (walking, laboratory
testing) used to establish the exercise prescription;
The target level of saturation during exercise and
the percentage of time during the test in which
this target had to be achieved.
81% of respondents individualized the oxygen
prescription at rest.
Resting SaO2 was most commonly targeted at
90–91%.
The approach to night prescription varied.
Respirologists in Canada and the USA increased
the resting SaO2 by 1–2 L/min during sleep, while
those in Spain used the resting flow for the night
prescription (62%).
Respirologists in the Netherlands, France, and
Italy individualized the night prescription more
frequently.
Although oxygen during exercise was
individualized in most countries (74%), significant
differences remained among countries.
62% of respirologists (62%) aimed to achieve an
SaO2 of 90–91% during exercise, while 70% of all
respirologists tried to achieve the desired SaO2 for
90% of the test.
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de Lucas
Ramos et al.,
2000 [4]
Spain, 1998–1999 HMV: prescription
Questionnaire mailed to the
respiratory medicine
departments of 200 hospitals in
the public health system
Survey Content:
Center name,
Year of initiation of the MV program,
Number of patients in the first year,
Number of patients in the current year.
Diagnosis:
Neuromuscular disease,
Thoracic cage disease,
Hypoventilation-obesity syndrome,
COPD,
Other.
Ventilation type:
Volumetric,
BI-level Positive Airway Pressure,
Interface,
Nasal mask,
Conventional,
Personalized,
Tracheostomy,
Mouthpiece.
43 hospitals, 1821 patients;
813 patients had restrictive disease due to thoracic
cage disease, 452 neuromuscular disease, 271
hypoventilation-obesity syndrome, 162 COPD,
and 123 other diseases/conditions.
965 (53%) used pressure support devices and 856
(47%) used volumetric ventilators.
1320 conventional nasal mask, 336 personalized
nasal mask, 118 tracheostomy, 41 facial mask, six
mouthpiece.
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Fauroux et al.,
1994 [19]
13 European
countries (Belgium,
Denmark, England,
France, Germany,
Ireland, Italy,
Netherlands,
Norway, Poland,
Spain, Sweden,
Switzerland), 1992
Home care of chronic
respiratory insufficiency Questionnaire at the end of 1992.
Questionnaire content:
Home treatments (LTOT, HMV);
Prescribers;
Practical organization of home care (supply of
material, supervision of patients and equipment).
Information on patients:
diagnostic information (either obstructive,
restrictive, or mixed pulmonary disease);
Age;
Sex;
Equipment supplied;
Service provided;
Therapeutic schedules.
Information was easier to obtain for LTOT than for
HMV.
In all countries, both adults and children received
LTOT at home for lung diseases and other less
common problems, such as chest-wall deformities
and sequelae of tuberculosis.
Oxygen concentrators were used preferentially in
all countries except Italy (80% of the patients
received liquid oxygen), Denmark, Spain, and the
Netherlands (cylinders were used by 80% of the
patients).
Both adults and children received HMV at home
for chronic lung disease, neuromuscular disease,
chest-wall deformities, and central
hypoventilation in all countries, except in
Denmark and Poland, where this treatment is
almost unknown in the home.
Home ventilator treatment was generally
performed by volume-cycled ventilators.
National prescription rules existed in some parts
of Spain, Switzerland, and Belgium. In other
countries, such as Germany, prescriptions relied
on recommendations elaborated by specialists or
international guidelines.
Service and equipment were provided by national
organizations, health services, commercial
companies, or hospitals.
Home supervision of the patient was performed
by a nurse and/or a doctor and equipment
maintenance by a technician.
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Most studies included both children and adult patients in their analysis. Only one of the studies
specifically focused on a pediatric population [18]. Questionnaires, having been used in 10 studies,
were the preferred method of data collection. In five studies, existing databases from HRT registries or
health services were used. Irrespective of the data collection method used, data on users (age, sex,
and diagnosis), type and duration of respiratory therapy, and equipment and interfaces were the most
commonly recorded. None of the 15 studies reported the patient’s experience with HRT.
2.2. Assessment of Patient Experience
Assessing the patient experience has become a common approach to describing healthcare from
the patient’s point of view, evaluating the process of care, and measuring the outcome of care [25–27].
Both quantitative and qualitative methods are being used to assess patients’ perception. Self-reported
questionnaires, individual interviews, and focus groups are among the most frequently used methods
of collecting data.
2.2.1. Patient-Reported Experience Measures
The development of self-reported questionnaires, namely, patient-reported experience measures
(PREMs) and patient-reported outcome measures (PROMs), has exponentially increased in the last
several years. These two types of questionnaires collect information about the patient’s perspective
but with distinct purposes. A PREM evaluates patients’ perception of their personal experience of the
healthcare received, while a PROM assesses the perception of their health status and health-related
quality of life [10,28]. A combination of PROMs and PREMs is essential to fully understand the
performance of healthcare systems. Moreover, both measures are useful to provide a patient-centered
perspective of healthcare, but PREMs are more adequate to assess experience with healthcare.
Distinct instruments to assess the patient’s experience with healthcare are available. Table 2 summarizes
14 instruments designed to assess the patient’s experience with the provision of care in different clinical
settings [29–34], hospital [35–38], primary care [39,40], intermediate care [41], and community [33,41].
The majority of such instruments are generic and designed to be used for a diverse range of health
conditions. However, two of the described questionnaires were specifically developed for patients with
chronic diseases [29,34], and one was intended particularly for patients with COPD [30]. The majority of
PREMs were developed to target adult patients and tested in patients who were at least 15 years old. Only
two developed instruments were tested with the carers of children [31,39]. English is the most common
language used, with some instruments also in Norwegian [31,38,39], Italian [35,41], and Spanish [29].
Most instruments already had some of their psychometric properties explored, namely, their reliability
and validity.
None of the instruments above were specifically designed to assess the patient’s experience with
HRT. However, a recent European Respiratory Society (ERS)/European Lung Foundation (ELF) survey
was conducted across 11 European countries and assessed the attitudes and preferences of 687 patients
on HMV and those of 100 carers [42]. A questionnaire was specifically developed for this study in eight
languages (English, German, Dutch, Spanish, Italian, Portuguese, Greek, and French) and explored
four areas: (1) patients’ demographic and clinical characteristics; (2) issues influencing compliance,
such as interface comfort, abilities to travel, sleep, and socialize with a ventilator, type and technical
functioning of the ventilator (e.g., alarms, ability to operate and change settings, on/off switches, and
electricity consumption); (3) support, training, and education; and (4) requests for improved devices
and support.
Today, it is possible to evaluate a patient’s perception of the HRT received using one of the
described PREMs. Nevertheless, in the near future, the aim should be to develop a specific PREM to
assess patients’ personal experience with HRT.
J. Clin. Med. 2019, 8, 555 15 of 24
Table 2. Instruments designed to assess patient’s experience with the provision of care.
Instrument Population Setting Language Concepts Structure MeasurementProperties
CEFIT: Care Experience
Feedback Improvement
Tool [36]
Tested in 802 patients
(≥18 years) with
healthcare experience.
Hospital English
Safe,
Timely,
System navigation,
Caring,
Effective.
Five questions scored
using a five-point scale,
from 1 (never) to 5
(always).
Reliability
Validity
COPD PREM9:
disease-specific
patient-reported
experience measure in
COPD [28,30]
Tested in 174 adult
patients with COPD.
Clinical settings (e.g.,
pulmonary rehabilitation,
nurse-led clinics, or GP
annual reviews)
English
Everyday life with COPD,
Everyday care in COPD,
Self-management of
COPD, exacerbations.
Nine questions scored
using a six-point scale,
from 0 (good experience)
to 5 (bad experience).
Reliability
Validity
GS-PEQ: Generic Short
Patient Experiences
Questionnaire [31]
Tested in 1324
patients (including
outpatients
undergoing
rehabilitation and
carers of children).
Services provided in a
range of specialist
healthcare (in- and
out-patient)
Norwegian
Outcome,
Clinician services,
User involvement,
Incorrect treatment,
Information,
Organization,
Accessibility.
10 questions scored using
a five-point scale, from 1
(Not at all/Not important)
to 5 (To a very large
extent/Of utmost
importance).
Not reported
howRwe (how are we
doing?)questionnaire:
short generic patient
experience questionnaire
[32,43]
Tested in 828 patients
in an orthopedic
pre-operative
assessment clinic [32]
and in 90 adult
patients (≥18 years)
from general practices
(10 with COPD) [43].
Generic, applicable
without change across all
patient categories and
care settings, including
primary, secondary,
community, emergency,
domiciliary, and social
care.
English Dutch
Clinical care (kindness
and communication),
Organization of care
(promptness and
organization).
Four items scored using a
four-point scale from 0
(poor) to 3 (excellent).
Reliability
Validity
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Table 2. Cont.
Instrument Population Setting Language Concepts Structure MeasurementProperties
Health Services
OutPatient Experience
(HSOPE): global outcome
measure of perceived
patient-centeredness of
the outpatient healthcare
pathway [35]
Tested in 1532 adult
outpatients (≥16
years) receiving care
(including
rehabilitation).
Hospital Italian
Perceived technical
effectiveness of the staff,
Information on
modalities of the
outpatient visit, on the
visit outcomes, and the
course of the healthcare
pathway,
Relational aspects of
outpatient–staff
interaction,
Involvement in decision
making.
10 statements scored
using a five-point Likert
scale from 1 (never) to 5
(always)
1 item scored using a
10-point scale from 1
(very dissatisfied) to 10
(very satisfied).
Three sociodemographic
questions (sex, age, and
residence).
One question about
suggestions to improve
outpatient visits.
Reliability
Validity
Intermediate
care-IC-PREMs:
Bed-Based
Patient-Reported
Experience Measure [41]
Tested in 1832 adult
patients. Bed-based IC services English Italian
Goal Setting,
Empowerment,
Self-Management,
Care-Planning,
Transitions,
Decision Making,
Communication.
15 questions scored using
two, three, or four
response categories.
Reliability
Validity
IC-PREMs: home-based
(and reablement-based)
Patient-Reported
Experience Measure [41]
Tested in 4627 adult
patients.
Home-based or
reablement IC services English Italian
Goal Setting,
Empowerment,
Self-Management,
Care-Planning,
Transitions,
Decision Making,
Communication.
15 questions scored using
two, three, or four
response categories.
Reliability
Validity
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Table 2. Cont.
Instrument Population Setting Language Concepts Structure MeasurementProperties
IEXPAC, Instrument for
Evaluation of the
Experience of Chronic
Patients [29]
Tested in 356 patients
(≥16 years) with
chronic diseases (20%
with COPD).
Health and social services Spanish
Type and scope of patient
and professional
interactions oriented to
patient activation.
Patient’s
self-management capacity
of his/her wellbeing
resulting from the
interventions received.
New relational model of
the patient with the
system through the
internet or with partners
in group intervention.
11 + 1 items scored using
a five-point scale from 0
(never) to 10 (always).
Since 2018, a new version
with 11 + 4 items is used,
with three additional
items.
Reliability
Validity
LifeCourse experience
tool [33]
Tested in 607 adult
patients with
emergency
department and
in-patient utilization,
advanced primary
diagnosis of heart
failure, cancer, or
dementia.
Home, Nursing Homes,
Assisted living English
Care Team,
Communication,
Care Goals.
22 items scored using a
four-point scale from 1
(Never or Strongly
Disagree) to 4 (Always or
Strongly Agree).
Reliability
Validity
Multidimensional
Semantic Patient
Experience Measurement
Questionnaire [37]
Tested in 60 patients
(≥15 years)
undergoing a
magnetic resonance
scan.
Hospital English
Evaluation/valence,
Potency/control,
Activity/arousal,
Novelty.
12 rating scales using a
seven-point bipolar
attribute rating scales:
‘extremely’, ‘quite’,
‘slightly’, ‘neither’,
‘slightly’, ‘quite’, and
‘extremely’.
Reliability
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Table 2. Cont.
Instrument Population Setting Language Concepts Structure MeasurementProperties
PEQ: Patient experience
questionnaire 2001 [39]
Tested in 1092
patients (1–91
years)/carers
Primary care Norwegian
Communication,
Emotions,
Short-term outcome,
Barriers,
Relations with auxiliary
staff.
Total 18 items:
Four items using a
five-point scale from 1
(‘no more’ or ‘nothing’) to
5 (‘much more’ or ‘a lot’).
10 items using a
five-point scale from 1
(disagree completely) to 5
(agree completely).
Four items were formed
on seven-point scales.
Reliability
Validity
PEQ: Patient Experiences
Questionnaire 2004 [38]
Tested in 19578
patients (≥16 years)
with experience with
surgical wards and
wards of internal
medicine
Hospital Norwegian
Information on future
complaints,
Nursing services,
Communication,
Information
examinations,
Contact with next-of-kin,
Doctor services,
Hospital and equipment,
Information medication,
Organization,
General satisfaction.
35 items with 10-point
ordinal response scales
from 1 (negative) to 10
(positive).
Reliability
Validity
PACIC: Patient
Assessment of Chronic
Illness Care [34,44]
Tested in 4108 adult
patients with diabetes,
chronic pain, heart
failure, asthma,
coronary artery
disease.
Chronic care
management English
Patient activation,
Delivery system design,
Goal setting,
Problem solving,
Follow-up/coordination.
Focuses on the receipt of
patient-centered care and
self-management
behaviors.
20 items using a
five-point scale from 1
(Almost Never) to 5
(Almost Always).
Reliability
Validity
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Table 2. Cont.
Instrument Population Setting Language Concepts Structure MeasurementProperties
ACES-SF: Ambulatory
Care Experiences Survey
[40]
Tested in 49,861 adult
patients. Primary care English
Quality of
physician–patient
interaction,
Health promotion
support,
Care coordination,
Organizational access,
Office staff interactions,
An additional item to
assess patients’
willingness to
recommend the physician
to family and friends.
18 items using continuous
responses: Never, Almost
never, sometimes,
Usually, Almost always,
Always; or Yes, definitely,
Yes, somewhat, No,
definitely not; or
Definitely yes, Probably
yes, Not sure, Probably
not, Definitely not.
Reliability
Validity
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2.2.2. Individual Interviews and Focus Groups
Qualitative studies that explore the experience of patients receiving HRT are still limited in the
literature. Nevertheless, the literature review revealed some studies that explored the experience of
patients living with COPD, pulmonary fibrosis, and OSA. These studies specifically focused on patients’
needs and the adaptation process to respiratory therapies. Two studies explored the patient’s experience
with LTOT [45,46], and the others assessed the patient’s experience with non-invasive ventilation [47–51].
These studies were conducted in the United States of America [45,47], New Zealand [48,49], the United
Kingdom [50], Sweden [51], and Spain [46] and included both adult patients and carers. Two reviews
were also found on the needs of patients with COPD and were also used in the present analysis [52,53].
From the analysis of these studies, it was possible to clearly identify education, training, support,
and carer involvement as important key-points in facilitating a patient’s treatment experience and
subsequent adherence. Below, each one of these four key-points is described in detail.
Education: on the basis of the perspectives of patients, it is apparent that education is crucial for
defining clear expectations about the treatment and motivating patient adherence. The main education
topics raised by patients receiving respiratory therapies are related to disease self-management
(e.g., COPD, OSA); physical effects and potential clinical benefits of the respiratory therapy; risks of
not using the respiratory therapy; guidance on the use and function of equipment (e.g., continuous
positive airway pressure (CPAP) devices, oxygen concentrators, how to use pulse oximeters and adjust
flow with exertion); side effects and guidance on its management (skin protection, dry mouth, nasal
congestion, irritated eyes); traveling with equipment; follow-up appointments; and assistance with
financial elements (e.g., how to claim electricity costs) [45,46,49,50].
Training: formal training on appropriate equipment use has been suggested to be an important
strategy for improving adherence [46–51]. Healthcare professionals need to introduce the device, explore
possible practical problems, and give advice/help to solve these problems. In their initial experiences with
respiratory therapy, patients should have a hands-on demonstration for setting up the device, trialing
different masks/pressures, making mask adjustments, conquering different side-effects, and finding the
best position for the tubing or machine (also considering the loudness of the device). Regular follow up
visits or phone calls are important to assess practical problems being experienced (e.g., pressure from
the mask, mask leakage, disturbing noise, and difficulties changing sleeping positions) and to discuss
effective strategies to address them.
Support: establishing a trustworthy relationship with healthcare professionals after the initiation of
respiratory therapy is perceived as helpful by patients, and these relationships positively influence their
adherence [46]. Healthcare professionals need to foster a non-judgmental environment in which patients
have opportunities to ask questions, share concerns and feelings, feel listened to, and feel understood.
This is particularly important following the initiation of therapy [47], as questions or concerns are more
likely to arise during the first days or weeks of treatment [49,52]. These opportunities can arise during
regular follow-up visits, scheduled follow-up phone calls, and through access to a 24-h hotline [47].
Carer involvement: carers provide substantial care (emotional, physical) to the individual on
a daily basis and, most of the time, live in the same house as the patient. On the basis of their
important role in patients’ lives, carer involvement has been found to be essential to patients receiving
HRT [45–48,50–53]. Patients recognize that carers play a major role in their treatment by helping them
manage the disease and adapt to the equipment (e.g., verbal reminders, encouragement, setting up the
machine, making mask adjustments, reassurance of therapy benefits). Carers themselves recognize their
need for information regarding aspects of the disease and benefits of the HRT [47]. Carer involvement
is thus perceived by all stakeholders as an essential component of education and training from the
beginning of treatment [45,47,48,50–53], and it is generally associated with positive results, namely,
the patients’ adoption and adherence to HRT [47,53].
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3. Discussion
This comprehensive review is a first critical step toward the assessment of the patient experience
in the clinical context of HRT. It demonstrates that research in this area is still limited, with no example
of an HRT prescription model that incorporates the patient experience as an outcome and with no
specific PREM available. This review also shows that European countries have been involved in HRT
provision research from an early stage.
Most of the research on the assessment of HRT prescription models has been conducted within
the last decade and mainly in European countries, highlighting the emergent interest and Europe’s
leading position in this area of health research. In addition, HMV has attracted more attention from
the scientific community in comparison with LTOT. Questionnaires were found to be the preferred
method for data collection, however, existing databases from HRT registries or health services have
also been used. Databases in comparison with questionnaires have the advantage of generating more
representative data and may be a method of choice in future studies. The patient experience has not
been examined in the assessment of the prescription models presented. While this reality was expected
from the oldest studies, it was quite a surprising result for those from the last decade. These results
show that, until now, the assessment of patients’ perceptions has not been seen as a priority in the
assessment of prescription models. Unfortunately, this is also a reality in other health contexts and
settings [10]. The Organisation for Economic Co-operation and Development (OECD) and Europe in
“Health at a Glance: Europe 2018” reported critical gaps in the data on patient-reported experience,
and they recommended collecting data on the patient experience from any doctor in ambulatory care
settings [10]. Thus, future studies on the provision of HRT should address this important gap in
the literature.
To address this gap, we need to be aware of the current methods being used to assess the patient
experience. Different instruments used at distinct levels of healthcare are available and described
in this review. These instruments were developed to be completed by adult patients and, in some
cases, by carers of children. In our opinion, although the carers’ perspective is, of course, incredibly
valuable, it should do not replace the children’s experience. The development of PREMs for pediatric
populations is crucial to the collection of information on the experience and outcome of children’s
care. Additionally, as previously mentioned, none of the instruments have been specifically designed
to assess the patient’s experience with HRT. The development of a specific PREM for this health
context should be a research priority in the upcoming years. The most commonly assessed domains
in the described instruments, including the ERS/ELF survey, together with the key facilitators of the
patient’s treatment experience, can be used as important sources of data to inform the development
of a comprehensive instrument. Access to information and support, implementation of effective
and clear communication, active participation in shared decision making, enhanced accessibility and
navigability across the healthcare system for patients and families, particularly across transitional care,
and management of polypharmacy are known to influence the patient experience in other healthcare
settings and could be topics of interest to be included in future PREMs for patients on HRT [54]. Future
studies should explore which of these raised topics are indeed meaningful for patients and carers.
On the basis of qualitative studies, it was found that education, training, support, and carer
involvement were important key-points in facilitating the patient’s treatment experience and adherence.
This knowledge comes mainly from the perspective of adult patients with COPD, pulmonary fibrosis,
and OSA receiving CPAP and from their carers. These studies were conducted in five countries (three
from Europe) [45–53]. Thus, this evidence may not completely apply to the experience of younger
patients (including children) and that of their carers or to patients with other diseases and other
treatment modalities (e.g., Bilevel Positive Pressure Airway, LTOT) and from other countries/continents.
Considering these identified gaps, the experience of other patients receiving HRT could be explored
in future studies. The identified key-points may inform the development process of semi-structured
guides of focus groups or individual interviews to be used in these exploratory studies.
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4. Conclusions
To the authors’ best knowledge, this is the first published work to review the emerging topic
of the patient experience in the clinical context of HRT and give important insights into the status
of this clinical research area while also pointing out possible directions in which to move to realize
patient-centered care. The assessment of the patient experience is in its early stages, and further
research is needed to integrate these measures with routine healthcare delivery and the core set of
healthcare quality indicators, as well as and to drive quality improvements in HRT.
Author Contributions: Conceptualization, C.C., C.J., J.A.F., J.E., and J.C.W.; writing—original draft preparation,
C.C. and C.J.; writing-review and editing, S.M.A., J.R.C., J.A.F., J.E., and J.C.W.; project administration, C.C.,
S.M.A., J.R.C., and J.C.W.
Funding: C.J. has a post-doctoral grant (SFRH/BPD/115169/2016) funded by Fundação para a Ciência e a Tecnologia
(FCT), co-financed by the European Social Fund (POCH) and Portuguese national funds from MCTES (Ministério
da Ciência, Tecnologia e Ensino Superior).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Cranston, J.; Crockett, A.; Moss, J.; Alpers, J. Domiciliary oxygen for chronic obstructive pulmonary disease.
Cochrane Database Syst. Rev. 2005, 4, CD001744. [CrossRef] [PubMed]
2. Annane, D.; Orlikowski, D.; Chevret, S. Nocturnal mechanical ventilation for chronic hypoventilation in
patients with neuromuscular and chest wall disorders. Cochrane Database Syst. Rev. 2014, 12, CD001941.
[CrossRef] [PubMed]
3. Melo, I. Alguns dados sobre a Assistência Respiratória Domiciliária em Portugal. Rev. Port. Pneumol. 1997, 3,
481–492. [CrossRef]
4. De Lucas Ramos, P.; Rodríguez González-Moro, J.M.; Santa-Cruz Siminiani, A.; Cubillo Marcos, J.M.; Paz
González, L. Estado actual de la ventilación mecánica domiciliaria en España: Resultados de una encuesta
de ámbito nacional. Arch. Bronconeumol. 2000, 36, 545–550. (In Spanish) [CrossRef]
5. Lloyd-Owen, S.J.; Donaldson, G.C.; Ambrosino, N.; Escarabill, J.; Farre, R.; Fauroux, B.; Robert, D.;
Schoenhofer, B.; Simonds, A.K.; Wedzicha, J.A. Patterns of home mechanical ventilation use in Europe:
Results from the Eurovent survey. Eur. Respir. J. 2005, 25, 1025–1031. [CrossRef] [PubMed]
6. World Health Organization. What is Quality of Care and Why Is It Important? Available online: http:
//www.who.int/maternal_child_adolescent/topics/quality-of-care/definition/en/ (accessed on 11 April 2019).
7. Simonds, A.K. Home Mechanical Ventilation: An Overview. Ann. Am. Thorac. Soc. 2016, 13, 2035–2044.
[CrossRef]
8. Dogan, O.T.; Turkyilmaz, S.; Berk, S.; Epozturk, K.; Akkurt, I. Effects of long-term non-invasive home
mechanical ventilation on chronic respiratory failure. Curr. Med. Res. Opin. 2010, 26, 2229–2236. [CrossRef]
9. NHS Department of Health. High Quality Care for All: NHS Next Stage Review Final Report; Norwich, UK, 2008.
Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_
data/file/228836/7432.pdf (accessed on 11 April 2019).
10. OECD/EU. Health at a Glance: Europe 2018: State of Health in the EU Cycle. OECD Publishing: Paris,
France, 2018. Available online: https://doi.org/10.1787/health_glance_eur-2018-en (accessed on 11 April
2019).
11. Doyle, C.; Lennox, L.; Bell, D. A systematic review of evidence on the links between patient experience and
clinical safety and effectiveness. BMJ Open 2013, 3, e001570. [CrossRef]
12. Rose, L.; McKim, D.A.; Katz, S.L.; Leasa, D.; Nonoyama, M.; Pedersen, C.; Goldstein, R.S.; Road, J.D. Home
mechanical ventilation in Canada: A national survey. Respir. Care 2015, 60, 695–704. [CrossRef]
13. Escarrabill, J.; Tebe, C.; Espallargues, M.; Torrente, E.; Tresserras, R.; Argimon, J. Variability in home
mechanical ventilation prescription. Arch. Bronconeumol. 2015, 51, 490–495. [CrossRef]
14. Nasilowski, J.; Wachulski, M.; Trznadel, W.; Andrzejewski, W.; Migdal, M.; Drozd, W.; Pytel, A.; Suchanke, R.;
Czajkowska-Malinowska, M.; Majszyk, T.; et al. The evolution of home mechanical ventilation in poland
between 2000 and 2010. Respir. Care 2015, 60, 577–585. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 555 23 of 24
15. Garner, D.J.; Berlowitz, D.J.; Douglas, J.; Harkness, N.; Howard, M.; McArdle, N.; Naughton, M.T.; Neill, A.;
Piper, A.; Yeo, A.; et al. Home mechanical ventilation in Australia and New Zealand. Eur. Respir. J. 2013, 41,
39–45. [CrossRef] [PubMed]
16. Mandal, S.; Suh, E.; Davies, M.; Smith, I.; Maher, T.M.; Elliott, M.W.; Davidson, A.C.; Hart, N. Provision of
home mechanical ventilation and sleep services for England survey. Thorax 2013, 68, 880–881. [CrossRef]
17. Chu, C.M.; Yu, W.C.; Tam, C.M.; Lam, C.W.; Hui, D.S.; Lai, C.K. Home mechanical ventilation in Hong Kong.
Eur. Respir. J. 2004, 23, 136–141. [CrossRef]
18. Fauroux, B.; Boffa, C.; Desguerre, I.; Estournet, B.; Trang, H. Long-term noninvasive mechanical ventilation
for children at home: A national survey. Pediatr. Pulmonol. 2003, 35, 119–125. [CrossRef] [PubMed]
19. Fauroux, B.; Howard, P.; Muir, J.F. Home treatment for chronic respiratory insufficiency: The situation in
Europe in 1992. The European Working Group on Home Treatment for Chronic Respiratory Insufficiency.
Eur. Respir. J. 1994, 7, 1721–1726. [CrossRef]
20. Ekstrom, M.; Ahmadi, Z.; Larsson, H.; Nilsson, T.; Wahlberg, J.; Strom, K.E.; Midgren, B. A nationwide
structure for valid long-term oxygen therapy: 29-year prospective data in Sweden. Int. J. Chron. Obstruct.
Pulmon. Dis. 2017, 12, 3159–3169. [CrossRef] [PubMed]
21. Ringbaek, T.J.; Lange, P. Trends in long-term oxygen therapy for COPD in Denmark from 2001 to 2010.
Respir. Med. 2014, 108, 511–516. [CrossRef]
22. Serginson, J.G.; Yang, I.A.; Armstrong, J.G.; Cooper, D.M.; Matthiesson, A.M.; Morrison, S.C.; Gair, J.M.;
Cooper, B.; Zimmerman, P.V. Variability in the rate of prescription and cost of domiciliary oxygen therapy in
Australia. Med. J. Aust. 2009, 191, 549–553.
23. Jones, A.; Wood-Baker, R.; Walters, E.H. Domiciliary oxygen therapy services in Tasmania: Prescription,
usage and impact of a specialist clinic. Med. J. Aust. 2007, 186, 632–634. [PubMed]
24. Wijkstra, P.J.; Guyatt, G.H.; Ambrosino, N.; Celli, B.R.; Güell, R.; Muir, J.F.; Préfaut, C.; Mendes, E.S.;
Ferreira, I.; Austin, P.; et al. International approaches to the prescription of long-term oxygen therapy.
Eur. Respir. J. 2001, 18, 909–913. [CrossRef] [PubMed]
25. Sitzia, J.; Wood, N. Patient satisfaction: A review of issues and concepts. Soc. Sci. Med. 1997, 45, 1829–1843.
[CrossRef]
26. Donabedian, A. Evaluating the Quality of Medical Care. Milbank Q. 2005, 83, 691–729. [CrossRef] [PubMed]
27. Tarlov, A.R.; Ware, J.E., Jr.; Greenfield, S.; Nelson, E.C.; Perrin, E.; Zubkoff, M. The Medical Outcomes Study.
An application of methods for monitoring the results of medical care. JAMA 1989, 262, 925–930. [CrossRef]
[PubMed]
28. Hodson, M.; Andrew, S.; Michael Roberts, C. Towards an understanding of PREMS and PROMS in COPD.
Breathe 2013, 9, 358–364. [CrossRef]
29. Mira, J.J.; Nuno-Solinis, R.; Guilabert-Mora, M.; Solas-Gaspar, O.; Fernandez-Cano, P.; Gonzalez-Mestre, M.A.;
Contel, J.C.; Del Rio-Camara, M. Development and Validation of an Instrument for Assessing Patient
Experience of Chronic Illness Care. Int. J. Integr. Care 2016, 16, 13. [CrossRef] [PubMed]
30. Hodson, M. Development of a Patient Reported Experience Measure in Chronic Obstructive Pulmonary
Disease (COPD). Ph.D. Thesis, University of Portsmouth, Hampshire, UK, 2018.
31. Sjetne, I.S.; Bjertnaes, O.A.; Olsen, R.V.; Iversen, H.H.; Bukholm, G. The Generic Short Patient Experiences
Questionnaire (GS-PEQ): Identification of core items from a survey in Norway. BMC Health Serv. Res. 2011,
11, 88. [CrossRef]
32. Benson, T.; Potts, H.W. A short generic patient experience questionnaire: howRwe development and
validation. BMC Health Serv. Res. 2014, 14, 499. [CrossRef]
33. Fernstrom, K.M.; Shippee, N.D.; Jones, A.L.; Britt, H.R. Development and validation of a new patient
experience tool in patients with serious illness. BMC Palliat. Care 2016, 15, 99. [CrossRef]
34. Schmittdiel, J.; Mosen, D.M.; Glasgow, R.E.; Hibbard, J.; Remmers, C.; Bellows, J. Patient Assessment of Chronic
Illness Care (PACIC) and improved patient-centered outcomes for chronic conditions. J. Gen. Intern. Med. 2008,
23, 77–80. [CrossRef]
35. Coluccia, A.; Ferretti, F.; Pozza, A. Health Services OutPatient Experience questionnaire: Factorial validity and
reliability of a patient-centered outcome measure for outpatient settings in Italy. Patient Relat. Outcome Meas.
2014, 5, 93–103.
J. Clin. Med. 2019, 8, 555 24 of 24
36. Beattie, M.; Shepherd, A.; Lauder, W.; Atherton, I.; Cowie, J.; Murphy, D.J. Development and preliminary
psychometric properties of the Care Experience Feedback Improvement Tool (CEFIT). BMJ Open 2016, 6,
e010101. [CrossRef]
37. Kleiss, J.A. Preliminary Development of a Multidimensional Semantic Patient Experience Measurement
Questionnaire. Herd 2016, 10, 52–64. [CrossRef]
38. Pettersen, K.I.; Veenstra, M.; Guldvog, B.; Kolstad, A. The Patient Experiences Questionnaire: Development,
validity and reliability. Int. J. Qual. Health Care 2004, 16, 453–463. [CrossRef]
39. Steine, S.; Finset, A.; Laerum, E. A new, brief questionnaire (PEQ) developed in primary health care for
measuring patients’ experience of interaction, emotion and consultation outcome. Fam. Pract. 2001, 18,
410–418. [CrossRef]
40. Rodriguez, H.P.; von Glahn, T.; Grembowski, D.E.; Rogers, W.H.; Safran, D.G. Physician effects on racial
and ethnic disparities in patients’ experiences of primary care. J. Gen. Intern. Med. 2008, 23, 1666–1672.
[CrossRef]
41. Teale, E.A.; Young, J.B. A Patient Reported Experience Measure (PREM) for use by older people in community
services. Age Ageing 2015, 44, 667–672. [CrossRef]
42. Masefield, S.; Vitacca, M.; Dreher, M.; Kampelmacher, M.; Escarrabill, J.; Paneroni, M.; Powell, P.;
Ambrosino, N. Attitudes and preferences of home mechanical ventilation users from four European
countries: An ERS/ELF survey. ERJ Open Res. 2017, 3, 00015–02017. [CrossRef]
43. Hendriks, S.H.; Rutgers, J.; van Dijk, P.R.; Groenier, K.H.; Bilo, H.J.G.; Kleefstra, N.; Kocks, J.W.H.;
van Hateren, K.J.J.; Blanker, M.H. Validation of the howRu and howRwe questionnaires at the individual
patient level. BMC Health Serv. Res. 2015, 15, 447. [CrossRef]
44. Glasgow, R.E.; Wagner, E.H.; Schaefer, J.; Mahoney, L.D.; Reid, R.J.; Greene, S.M. Development and validation
of the Patient Assessment of Chronic Illness Care (PACIC). Med. Care 2005, 43, 436–444. [CrossRef]
45. Holm, K.E.; Casaburi, R.; Cerreta, S.; Gussin, H.A.; Husbands, J.; Porszasz, J.; Prieto-Centurion, V.;
Sandhaus, R.A.; Sullivan, J.L.; Walsh, L.J.; et al. Patient Involvement in the Design of a Patient-Centered Clinical
Trial to Promote Adherence to Supplemental Oxygen Therapy in COPD. Patient 2016, 9, 271–279. [CrossRef]
46. Clèries, X.; Solà, M.; Chiner, E.; Escarrabill, J. Aproximación a la experiencia del paciente y sus cuidadores en
la oxigenoterapia domiciliaria. Arch. Bronconeumol. 2016, 52, 131–137. (In Spanish) [CrossRef] [PubMed]
47. Luyster, F.S.; Dunbar-Jacob, J.; Aloia, M.S.; Martire, L.M.; Buysse, D.J.; Strollo, P.J. Patient and partner
experiences with obstructive sleep apnea and CPAP treatment: A qualitative analysis. Behav. Sleep Med.
2016, 14, 67–84. [CrossRef] [PubMed]
48. Ward, K.; Gott, M.; Hoare, K. Making choices about CPAP: Findings from a grounded theory study about
living with CPAP. Collegian 2017, 24, 371–379. [CrossRef]
49. Gibson, R.; Campbell, A.; Mather, S.; Neill, A. From diagnosis to long-term treatment: The experiences of
older New Zealanders with obstructive sleep apnoea. J. Prim. Health Care. 2018, 2, 140–149. [CrossRef]
[PubMed]
50. Gale, N.K.; Jawad, M.; Dave, C.; Turner, A.M. Adapting to domiciliary non-invasive ventilation in chronic
obstructive pulmonary disease: A qualitative interview study. Palliat. Med. 2015, 29, 268–277. [CrossRef]
[PubMed]
51. Brostrom, A.; Nilsen, P.; Johansson, P.; Ulander, M.; Stromberg, A.; Svanborg, E.; Fridlund, B. Putative
facilitators and barriers for adherence to CPAP treatment in patients with obstructive sleep apnea syndrome:
A qualitative content analysis. Sleep Med. 2010, 11, 126–130. [CrossRef]
52. Gardener, A.C.; Ewing, G.; Kuhn, I.; Farquhar, M. Support needs of patients with COPD: A systematic
literature search and narrative review. Int. J. Chron. Obstruct. Pulmon. Dis. 2018, 13, 1021–1035. [CrossRef]
[PubMed]
53. Katsenos, S.; Constantopoulos, S.H. Long-Term Oxygen Therapy in COPD: Factors Affecting and Ways of
Improving Patient Compliance. Pulm. Med. 2011, 2011, 325362. [CrossRef]
54. Fujisawa, R.; Klazinga, N.S. Measuring patient experiences (PREMS): Progress made by the OECD and its
member countries between 2006 and 2016. OECD Health Work. Pap. 2017. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
